AstraZeneca’s Farxiga (dapagliflozin) has been approved by the FDA to improve glycaemic control in paediatric patients with type-2 diabetes (T2D) aged 10 years and older. The FDA approval… read more.
Adjunctive dapagliflozin therapy appears to improve outcomes in heart failure patients without regard to frailty status at initiation of treatment. These findings appeared on April 26, 2022 in… read more.
Article written by Bruce Sylvester Patients with chronic kidney disease have achieved improved outcomes with dapagliflozin treatment, researchers reported on October 8, 2020 in the NEJM/New England Journal… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
